CUE Cue Biopharma Inc

Price (delayed)

$31.71

Market cap

$230.35M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$26.42

Enterprise value

$215.26M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 17
Highlights
CUE's debt has dropped by 60% year-on-year and by 11% since the previous quarter
CUE's revenue is up by 15% since the previous quarter
The company's equity has shrunk by 89% QoQ and by 87% YoY
The EPS has shrunk by 68% YoY

Key stats

What are the main financial stats of CUE

CUE stock price

How has the Cue Biopharma stock price performed over time
Intraday
2.62%
1 week
-7.2%
1 month
32.24%
1 year
48.94%
YTD
246.18%
QTD
0.48%

Financial performance

How have Cue Biopharma's revenue and profit performed over time
Revenue
$37.65M
Gross profit
$37.65M
Operating income
-$98.68M
Net income
-$164.11M
Gross margin
100%
Net margin
-435.8%
The company's operating income has shrunk by 151% YoY
Cue Biopharma's operating margin has increased by 45% YoY
CUE's revenue is up by 15% since the previous quarter
The gross profit is up by 15% since the previous quarter

Price vs fundamentals

How does CUE's price correlate with its fundamentals

Growth

What is Cue Biopharma's growth rate over time

Valuation

What is Cue Biopharma stock price valuation
P/E
N/A
P/B
55.54
P/S
5.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.72
The EPS has shrunk by 68% YoY
The company's equity has shrunk by 89% QoQ and by 87% YoY
The price to sales (P/S) is 87% lower than the 5-year quarterly average of 38.6 but 18% higher than the last 4 quarters average of 4.4
CUE's revenue is up by 15% since the previous quarter

Efficiency

How efficient is Cue Biopharma business performance
The ROIC has decreased by 16% YoY
The ROS is up by 6% YoY

Dividends

What is CUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CUE.

Financial health

How did Cue Biopharma financials performed over time
The total assets is 8% greater than the total liabilities
The current ratio has dropped by 65% since the previous quarter and by 22% year-on-year
Cue Biopharma's quick ratio has shrunk by 64% QoQ and by 29% YoY
CUE's debt is 33% greater than its equity
The company's equity has shrunk by 89% QoQ and by 87% YoY
CUE's debt has dropped by 60% year-on-year and by 11% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.